In the News

A study led by researchers from Vanderbilt-Ingram Cancer Center sheds light on some of the genetic variants that make breast cancer more deadly for women of African ancestry and significantly reduces the disparity in knowledge for assessing their genomic risk factors.

The TAILORx study published last year offered good news for women with early-stage ER-positive breast cancer who scored at intermediate risk for recurrence according to a genetic assay test. The study indicated that chemotherapy after surgery provided little advantage in overall survival for these women, so they could forgo the treatment.